Finanzen von Silence Therapeutics PLC (SLN)SLNSilence Therapeutics PLC

Evaluating the bottom line, Silence Therapeutics PLC maintains a gross margin of 97.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7014.69%, while the net margin is -6451.42%. These profitability ratios, combined with a Return on Equity (ROE) of -90.41%, provide a clear picture of how effectively SLN converts its operational activities into shareholder value.

In the context of the broader market, SLN competes directly with industry leaders such as KPLT and SBC. With a market capitalization of $539.50M, it holds a significant position in the sector. When comparing efficiency, SLN's gross margin of 97.39% stands against KPLT's 26.79% and SBC's 73.14%. Such benchmarking helps identify whether Silence Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Silence Therapeutics reported a gross margin of 97.39% in Q1 2026, indicating strong profitability on sales, but it has consistently posted net losses, including a net loss of $12.2 million in Q2 2026. Total revenue for Q1 2026 was $422,000, which is a positive trend compared to previous quarters.